PROTEIN TYROSINE PHOSPHATASE 1B (PTP1B) IN OBESITY AND TYPE 2 DIABETES
DOI:
https://doi.org/10.5457/ams.v38i1.23Keywords:
Type 2 diabetes, obesity, metabolic disease, protein tyrosine phosphatase 1B (PTP1B), insulin resistance, glucose homeostasis, leptin sensitivityAbstract
Increased incidence in obesity is reaching epidemic proportions and is placing a major burden on the healthcare systems in the developed countries. Obesity is a major risk factor for the development of type 2 diabetes, metabolic syndrome, cardiovascular disease and cancer. Thus, the search for molecules that regulate the development of obesity and its associated pathologies is ongoing. Protein tyrosine phosphatase 1B (PTP1B) has been found to be a major regulator of body fat stores, energy balance, and insulin sensitivity in vivo. Increased expression of PTP1B is associated with insulin resistance in rodents and humans and deletion of PTP1B leads to leanness and insulin sensitivity in rodents, suggesting that PTP1B may be a very attractive molecular target for anti-obesity, anti-diabetic agents.
Downloads
Published
Issue
Section
License
Copyright transfer
The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.
